- Formula re: Contains
- Bifidobacterium Longum Subsp. Infantis M-63
Bifidobacterium longum subsp. infantis (B. infantis) is associated with improved growth, the development of intestinal membrane integrity, and is critical for developing immune function. B. infantis is the predominant intestinal organism found in breast-fed infants. B. infantis M-63 was isolated from a healthy infant and clinically proven to colonize the intestines of infants. B. infantis is the only bacterial species able to take up and metabolize all Human Milk Oligosaccharides (HMOs) which allows B. infantis to outcompete other bacterial species.
Jarro-Dophilus Infant is formulated with Medium Chain Triglycerides (MCTs), which are naturally present in breast milk and are more easily absorbed by the newborn’s immature digestive system.
- General Statements: All Other Content
- The developing intestinal microflora of newborns is up to 90% B. infantis
- Suggested/Recommended/Usage/Directions
- Usage: For newborns to infants up to 6 months old, add 10 drops, once daily, to foods, lukewarm milk, or an infant formula. Or use as directed by your qualified healthcare professional. Shake bottle well before each use.
- FDA Disclaimer Statement
- These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.
- General Statements: All Other Content
- Strains Matter: Jarrow Formulas’ Probiotics contain clinically documented strains
- Storage
- No refrigeration necessary
Does not require refrigeration and best to store in cool, dry place. Avoid storage at temperature above 77°F (25°C).
- Brand IP Statement(s) re: (c), (TM), (SM)
- U.S. patent-pending
2018 Jarrow Formulas
- Formula re: Contains
- With clinically documented B. infantis M-63
Documented strain 1 billion live bacteria guaranteed
- Formulation re: Vegetarian/Vegan